Bioprojet
30
2
3
22
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
16.7%
5 terminated/withdrawn out of 30 trials
81.5%
-5.0% vs industry average
43%
13 trials in Phase 3/4
9%
2 of 22 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (30)
Proof of Concept Study on BP1.4979 Effect on Essential Tremor
Role: lead
Pilot Study on BP1.4979 Effect on Binge Eating Disorders
Role: lead
Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation
Role: lead
Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents
Role: lead
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
Role: lead
Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke
Role: lead
Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment
Role: lead
Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome
Role: lead
Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA
Role: lead
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
Role: collaborator
Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
Role: lead
Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users
Role: lead
Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)
Role: lead
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.
Role: lead
A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment
Role: lead
Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers
Role: lead
Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
Role: lead
Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)
Role: lead
BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.
Role: lead
Efficacy and Safety of BP1.4979 in Smoking Cessation
Role: lead